|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, the role of MDM2 and MDMX in the context of mtp53 in BCs requires further clarification.
|
31489110 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer.
|
30972184 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings suggest that SCF<sup>FBXO22</sup> targets HDM2 for degradation and possesses inhibitory effects against breast cancer tumor cell invasion and metastasis.
|
31138683 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Racial/ethnic differences in expression profiles of mtp53, MDM2, and MDM2-C and associations with breast cancer-specific and overall mortality.
|
30470976 |
2019 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα<sup>+</sup>) breast cancer and triple-negative breast cancer (TNBC).
|
30642351 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
|
29269425 |
2018 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population
|
29699057 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, oncoprotein HBXIP suppresses miR-18b to elevate MDM2 and activates pAKT to phosphorylate MDM2 for enhancing the interaction between MDM2 and p53, leading to p53 degradation in promotion of breast cancer growth.
|
30181579 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also propose several strategies for inhibiting the NFAT1-MDM2-p53 pathway, which could be useful for developing more specific and effective inhibitors for breast cancer therapy.
|
29096894 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We previously demonstrated that this estrogen-MDM2 axis activates the proliferation of breast cancer cell lines T47D (mtp53 L194F) and MCF7 (wild-type p53) in a manner independent of increased degradation of wild-type p53 (ie, p53-independently).
|
28615518 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
|
27826076 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Together, our finding revealed a novel modifier for p53/MDM2 complex and suggested SHARPIN as a promising target to restore p53 function in breast cancer.
|
28063307 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The role of MDM2 and MDM4 in breast cancer development and prevention.
|
28096293 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells.
|
28844019 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
|
28274247 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
|
27081698 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, these novel findings implicate ERα as a central component of the p53-MDM2-MDM4 signaling axis in human breast cancer.
|
26909605 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, by performing global sensitivity analysis on the landscape topography, six key genes (HER2, MDM2, TP53, BRCA1, ATM, CDK2) and four regulations (HER2⊣TP53, CDK2⊣BRCA1, ATM→MDM2, TP53→ATM) were identified as being critical for breast cancer.
|
27410227 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
While MDM2 (T309G) polymorphism may not be directly associated with the risk of breast cancer occurrence in the same population, but it may play role in disease progression by triggering TP53.
|
26553387 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, G613 represents a potent small-molecule inhibitor of the Mdm2-p53 interaction and can serve as a promising lead for developing a new class of anti-cancer therapy for breast cancer patients.
|
26556313 |
2016 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
p53 expression and relationship with MDM2 amplification in breast carcinomas.
|
27040927 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study provides a preclinical rationale for evaluation of MI-77301 or other MDM2 inhibitors as a new therapeutic strategy for the treatment of endocrine-resistant breast cancer retaining wild-type p53.
|
27765850 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the role of MDM2 in epithelial-to-mesenchymal transition (EMT) and the underlying mechanisms in breast cancer cells in vitro and in vivo.
|
27184007 |
2016 |